Manufacturer
Device name
Sheath diameter (French)
Sheath length (cm)
Needle gauge
Needle length (mm)
Boston Scientific (Natick, MA)
Interject sclerotherapy needle
7
200, 240
23, 25
4, 6
ConMed Endoscopic Technologies (Chelmsford, MA)
Click-Tip injection needle
7
180, 230
19, 22, 25
4, 6
Flexitip disposable sclerotherapy needle
7
180, 230
4, 5
Sure shot injection needle
7
160, 230
5
Cook Medical (Winston-Salem, NC)
Acujet variable injection needle
7
220
23, 25
Injectaflow variable injection needle
7
220
23, 25
Olympus America (Center Valley, PA)
Injector force injection needle
7
230
21, 23, 25
4, 5, 6, 8
US Endoscopy (Mentor, OH)
Articulator injection needle
7
160, 230, 350
25
4,5
Carr-Locke injection needle
7
230
25
5
Vari-Safe injection needle
7
230
23
4, 5, 7
Kimberly-Clark (Roswell, GA)
Injection needle catheter
7
160, 200, 240
23, 25
4, 6
Telemed Systems (Hudson, MA)
Sure-Stop sclerotherapy needle
5,7
160, 240
25
4, 5
Thermal Therapy
Thermal devices used in the treatment of GI bleeding include contact and noncontact modalities (Table 11.2). Contact thermal devices include heater probes, which generate heat directly at the tip of the probe, and bipolar electrocoagulation probes, which generate heat indirectly by passage of an electrical current between closely spaced electrodes at the tip of the probe. Noncontact thermal devices include argon plasma coagulation and laser therapy, although the latter is rarely used nowadays.
Table 11.2
Contact and noncontact thermal devicesa
Manufacturer | Device name | Sheath diameter (French) | Sheath length (cm) | Special features |
---|---|---|---|---|
Boston Scientific (Natick, MA) | Gold probe | 7, 10 | 300, 350 | |
Injector gold probe | 7, 10 | 210 | Integrated injection needle | |
ConMed Endoscopic Technologies (Chelmsford, MA) | Bicap superconductor, multielectrode bipolar probe | 5, 7, 10 | 200, 300, 350 | |
Palladium tip bipolar hemostasis probe | 7, 10 | 300 | ||
Beamer argon probe | 5, 7, 10 | 160, 230, 320 | ||
Cook Medical (Winston-Salem, NC) | Quicksilver bipolar probe | 7, 10 | 350 | |
Olympus America (Center Valley, PA) | Solar probe | 7, 10 | 350 | |
Heat probe | 7, 10 | 230, 300 | Reusable | |
Coagrasper | 7 | 165 | ||
US Endoscopy (Mentor, OH) | Bipolar hemostasis probe | 7, 10 | 350 | |
Canady (Hampton, VA) | Canady plasma GI probe | 5, 7 | 230, 340 | Straight, side fire |
ERBE (Marietta, GA) | APC probe | 5, 7, 10 | 50, 220, 300 | Straight |
FiAPC probe | 5, 7, 10 | 50, 220, 300 | Side circumferential fire |
Heat generated from these thermal devices leads to edema, coagulation of tissue proteins, contraction of vessels, and indirect activation of the coagulation cascade, resulting in a hemostatic bond [18, 20]. Heater and bipolar probes also benefit from local tamponade (mechanical pressure of the probe tip directly onto the bleeding site) combined with heat or electrical current to coagulate blood vessels, a process known as “coaptive coagulation .” This process minimizes the heat sink effect, whereby energy is lost due to blood flow through a non-compressed vessel.
The heater probe consists of a Teflon-coated hollow aluminum cylinder with an inner heating coil. A thermo-coupling device at the tip of the probe maintains a constant temperature. A foot pedal controls heat activation as well as water-jet irrigation through the probe. Heater probe activation delivers energy to the diode in the probe tip. Once the pulse has been initiated, the duration of activation is predetermined and cannot be stopped until the entire amount of preselected energy is delivered [21]. A setting of 30 J is suggested for peptic ulcer bleeding (Video 11.1) and gastric Dieulafoy lesions. A setting of 15 J is recommended for other lesions, such as a bleeding Mallory-Weiss tear and vascular ectasias.
The bipolar probe delivers thermal energy by completion of an electrical circuit between positive and negative electrodes on the tip of the probe as current flows through non-desiccated tissue. In contrast to monopolar devices, the electrical circuit is confined to the tip of the probe, and so no grounding pad is required. As the targeted tissue desiccates, there is decrease in electrical conductivity, thereby limiting the maximum temperature, depth, and area of tissue injury. A foot pedal controls the delivery of the energy in watts [20]. The usual setting for peptic ulcer bleeding and gastric Dieulafoy lesions is 20 W delivered in 7–10 s application (referred to as tamponade stations) prior to removal of the probe. Several applications, with moderate to firm probe-tissue contact pressure, may be required until active bleeding is controlled and/or white coagulum formation with shallow cavitation of the treated site is observed. A lesser amount of energy (12–15 W) and shorter application duration (3–5 s) are recommended for other lesions, such as a bleeding Mallory-Weiss tear and vascular ectasias. Similar to the heater probe, built-in water-jet irrigation in the bipolar probe facilitates identification and precise targeting of the actively bleeding point prior to coagulation and aids in sliding the probe off the coagulated, sticky tissue.
Argon plasma coagulation (APC) , a noncontact device, uses high-frequency monopolar alternating current conducted to the target tissue through a stream of ionized argon gas to achieve coagulation of superficial tissue [22]. As the coagulated tissue surface loses its electrical conductivity, the plasma stream shifts to adjacent non-desiccated (conductive) tissue, which again limits the depth of tissue injury [18]. If the APC catheter is too far from the target tissue, there is no ignition of the gas, and depression of the foot pedal results only in flow of inert argon gas. Coagulation depth is dependent on the generator power setting, duration of application, and distance from the probe tip to the target tissue [22, 23]. The optimal distance between the probe and target tissue ranges from 2 to 8 mm [24]. Commercially available APC systems (ERBE USA, Marietta, GA; ConMed Electrosurgery, Centennial, CO; Canady Technology, Pittsburgh, PA; Genii, St. Paul, MN) include a specialized electrosurgical generator capable of high-frequency monopolar current, an activation foot pedal, an argon gas cylinder, disposable grounding pads, and flexible single-use APC probes. An adjustable gas flowmeter allows argon gas flow rates of 0.5–7 l/min. APC probes are composed of Teflon with a ceramic tip encasing the tungsten electrode and are available as end-firing, side-firing, and circumferential-firing probes. APC is primarily used for the treatment of superficial mucosal vascular lesions, such as vascular ectasias and GAVE (Video 11.2). Suggested settings are a power of 30–45 W (depending on the APC generator utilized) and an argon flow rate of 1 l/min.
Mechanical Therapy
Endoscopic mechanical therapies include clips (Table 11.3) and band ligation devices. Through-the-scope (TTS) endoscopic clips are deployed directly onto the bleeding site (e.g., active bleeding, non-bleeding visible vessel) and typically fall off within days to weeks after placement [1, 25]. All endoscopic clipping devices have three primary components: a metallic double- or triple-pronged preloaded clip, a delivery catheter, and a handle to operate and deploy the clip. Clips are available in a variety of jaw lengths and opening widths. The delivery catheter consists of a metal cable with or without a protective sheath. The tip of the metal cable has a hook onto which the clip is attached. The handle consists of two sliding components: the first allows advancement of the metal cable holding the clip out of the protective sheath, if present, and the second is the plunger that controls the opening, closing, and deployment of the clip. After insertion of the clip through the working channel of the endoscope, the clip is extended out of the sheath, if one is present. The clip is then positioned over the target area and opened with the plunger handle. A rotation mechanism on the handle is available on some commercially available clips, and this allows the endoscopist to change the orientation of the clip at the site of bleeding. The jaws of the clip are applied with pressure and closed onto the target tissue by using the device handle [25, 26]. Some clips have reopening capabilities and can be repositioned, whereas others are permanently deployed and released upon clip closure. Similarly, some clips are automatically released on deployment, while others require repositioning of the plunger handle to release the deployed clip from the catheter. Hemostasis is achieved by mechanical compression of the bleeding site (Video 11.3). Both the operator and assistant should be well acquainted with the various clip deployment mechanisms so as to facilitate easy and efficient utilization. Clip selection is mostly dependent on device availability, operator preference, and familiarity with a particular clip.
Table 11.3
Clipping devicesa
Manufacturer | Device name | Sheath diameter (French) | Sheath length (cm) | Jaw opening width (mm) | Special features |
---|---|---|---|---|---|
Boston Scientific (Natick, MA) | Resolution clip | 7 | 155, 235 | 11 | 2-prong clip |
Cook Medical (Winston-Salem, NC) | Triclip | 7,8 | 207 | 12 | 3-prong clip |
Instinct clip | 7 | 230 | 16 | 2-prong clip rotatable | |
Olympus America (Center Valley, PA) | Quickclip 2 | 7 | 165, 230 | 9 | 2-prong clip rotatable |
Quickclip 2 long | 7 | 165, 230 | 11 | 2-prong clip rotatable | |
QuickClipPro | 7 | 165, 230 | 11 | 2-prong clip rotatable |
Emerging data suggest that the over-the-scope clip (OTSC; Ovesco, Tübingen, Germany), developed for closure of small mural defects, may also be effective for the management of focal non-variceal GI bleeding lesions (e.g., peptic ulcer, Dieulafoy lesion, post-polypectomy bleeding site) (Figs. 11.1 and 11.2) [27–29]. The OTSC may prove superior to standard TTS clips because of its ability to grasp more surrounding tissue and apply a greater compressive force (Video 11.4). However, no comparative data are available at this time. The OTSC device includes an applicator cap carrying the clip, a memory-shaped nitinol clip in the form of a bear claw when released, and a rotating hand wheel for clip deployment. The applicator cap with the mounted nitinol clip is affixed to the tip of the endoscope in a manner similar to that of a variceal band ligation device. Caps are available in three sizes to accommodate various endoscope diameters: 11 mm (designed for endoscope diameters 9.5–11 mm), 12 mm (for endoscope diameters 10.5–12 mm), and 14 mm (for endoscope diameters 11.5–14 mm). Caps are also available in two depths (3 and 6 mm) to allow variation in the amount of tissue desired during suction. Clips come in three different sizes to match the cap sizes and also in three different shapes of teeth: type A (rounded teeth), type T (pointed teeth), and type GC (longer pointed teeth). Clips with rounded teeth are used when the goal is tissue compression for hemostasis, particularly in the thinner-walled esophagus and colon. The applicator cap incorporates a clip release thread, which is pulled retrograde through the working channel of the endoscope and fixed onto a hand wheel mounted on the working channel access port of the endoscope. The clip is released by turning the hand wheel, in a manner similar to deploying a variceal ligation band [27].
Fig. 11.1
(a) Cap-assisted access to an actively bleeding duodenal ulcer in a difficult location. (b) Successful hemostasis achieved with placement of an over-the-scope clip
Fig. 11.2
(a) Duodenal Dieulafoy lesion . (b) Hemostasis achieved with placement of an over-the-scope clip
Endoscopic band ligation (EBL) devices , commonly used in esophageal variceal bleeding, can also be effective at treating select NVUGIB lesions. EBL involves placement of elastic bands under the suctioned target tissue to produce mechanical compression and tamponade (e.g., Dieulafoy lesion) (Fig. 11.3 and Video 11.5) [30].
Fig. 11.3
(a) Gastric Dieulafoy lesion . (b) Band ligation performed. (c) Post band ligation appearance
Emerging Endoscopic Techniques for NVUGIB
Video Capsule Endoscopy
Recently, video capsule endoscopy has been shown to be an effective method to identify acute upper GI bleeding in the emergency department. Capsule endoscopy identified gross blood in the upper GI tract, including the duodenum, significantly more often than nasogastric tube aspiration, and identified inflammatory lesions to a similar degree as EGD. Capsule endoscopy may also facilitate patient triage and earlier endoscopy but at this point in time should not be considered a substitute for EGD [31].
Capsule endoscopy only offers diagnostic capabilities and cannot offer the dual diagnostic and therapeutic advantage of EGD in the hands of a skilled endoscopist for the treatment of NVUGIB. The role of real-time capsule endoscopy might be in a setting where endoscopic services are not readily available and to ascertain the presence of upper GI bleeding before a patient is referred to a tertiary facility.
Topical Hemostatic Agents
Hemostatic sprays have been used thus far in a limited number of patients with acute upper and lower GI bleeding, with good results overall [32]. The advantages of noncontact spray catheter delivery of hemostatic agents include ease of use, lack of need for precise lesion targeting, access to lesions in difficult locations, and the ability to treat a larger area (Video 11.6). Various granules or powders have been used in military combat situations to treat compressible external hemorrhage in battlefield casualties. One of these compounds, TC-325 (Hemospray; Cook Medical Inc., Winston-Salem, NC), is currently undergoing evaluation as a hemostatic agent for endoscopic use [32, 33]. TC-325 is a proprietary, inorganic, absorbent powder that rapidly concentrates clotting factors at the bleeding site, forming an adherent coagulum. Hemospray is a handheld device consisting of a pressurized CO2 canister for delivery of the powder, a TTS delivery catheter, and a reservoir for the powder cartridge. The powder is delivered via push button in 1–2-s bursts until hemostasis is achieved. The maximum amount of TC-325 that can be safely administered during a single treatment session has not yet been established [32]. The coagulum typically sloughs within 3 days and is naturally eliminated. Hemospray has received regulatory clearance in some countries but is not yet approved by the US FDA.
Hemostatic sprays derived from plant products have also been evaluated. Clinical experience with these agents for endoscopic hemostasis is currently limited to the off-label use of the Ankaferd Blood Stopper (ABS; Ankaferd Health Products Ltd, Istanbul, Turkey), a mixture of extracts from several plants that is approved in Turkey for topical treatment of dental and postsurgical external bleeding [34–39]. ABS promotes formation of a protein mesh that acts as an anchor for erythrocyte aggregation without significantly altering coagulation factors or platelets. The ABS solution, available in 2-mL vials, is delivered onto the bleeding site via an endoscopic spray catheter until an adherent coagulum is formed [35]. EndoClot (EndoClot Plus Inc., Santa Clara, CA) consists of absorbable modified polymers and is intended to be used as an adjuvant hemostatic agent to control bleeding in the GI tract. It is a biocompatible, non-pyogenic, starch-derived compound that rapidly absorbs water from serum and concentrates platelets, red blood cells, and coagulation proteins at the bleeding site to accelerate the clotting cascade. The particles are subsequently cleared from the bleeding site with no remaining residue a few hours to days later. There are only scant data on this product’s safety or efficacy [35]. The current limited data demonstrate the potential for hemostatic sprays to be used as definitive or bridge therapy. The efficacy of these agents is unknown in brisk arterial bleeding and may be limited because of the rapid “wash-away” effect of the hemostatic agent by ongoing blood flow. The exact role and overall safety of hemostatic sprays remain to be delineated. Additional data and prospective comparative studies involving a larger number of subjects are needed.
Preprocedural Considerations
In addition to fluid resuscitation and correction of coagulopathy, as previously mentioned, an assessment should be made for preemptive endotracheal intubation for airway protection, particularly in the setting of active hematemesis, encephalopathy, and/or difficult airway (e.g., short, thick neck). The procedure should also be aborted temporarily if a large amount of retained blood and clots is found in the stomach at the time of endoscopy to enable airway protection for prevention of aspiration.
A dual channel or therapeutic channel (3.7 mm) upper endoscope is recommended for the assessment of acute upper GI bleeding. The larger working channel enables better suction capability and the passage of large (10 Fr) rather than small (7 Fr) diameter thermal probes for hemostasis. A pedal-activated water-jet irrigation device coupled to the entrance port of the working channel or built in the endoscope facilitates washing the mucosa of adherent bloody material and aids in precisely identifying the actively bleeding point for targeted hemostasis.
Common Causes of NVUGIB
Peptic Ulcer
Gastroduodenal ulcer remains the leading cause of acute NVUGIB. Mortality rates associated with peptic ulcer bleeding are still about 5–10 %. Endoscopic findings in peptic ulcer bleeding associated with increased morbidity and mortality include ulcer location (e.g., high lesser gastric curve, posterior duodenal bulb), ulcer size ≥ 2 cm, pulsatile arterial bleeding, and large bleeding vessel (≥2 mm) [6, 9]. Endoscopic assessment and risk stratification prior to application of a specific hemostatic technique are essential in guiding the appropriate endoscopic treatment of patients with acute upper GI bleeding due to peptic ulcer.
The endoscopic stigmata of an ulcer provide prognostic information regarding the risk of ongoing bleeding or rebleeding and the necessity for therapeutic intervention (Table 11.4). In Europe and Asia, the Forrest classification for stigmata of recent hemorrhage (Fig. 11.4) is commonly used, whereas in North America, descriptive terms are the norm. Most patients with ulcer bleeding have low-risk stigmata (flat pigmented spot or clean base) and thus do not require endoscopic hemostasis. High-risk stigmata (active bleeding, non-bleeding visible vessel, or adherent clot) are encountered in up to 35 % of patients with acute peptic ulcer bleeding [10, 40]. Active bleeding is subcategorized as spurting or oozing, although most studies of prevalence have combined these categories into “active ulcer bleeding” [41]. Results from prospective trials, however, suggest they should likely be viewed separately because the risk of further bleeding with spurting bleeding is higher than with oozing bleeding [42, 43].
Table 11.4
Rates of rebleeding before and after endoscopic therapy and rates of surgery and mortality with no endoscopic therapy, stratified by endoscopic stigmata
Endoscopic stigmata | Forrest classification | Prevalence (%) | Persistent bleeding or rebleeding with no endoscopic treatment (%) | Rebleeding after endoscopic hemostasis (%) | Surgery for bleeding with no endoscopic treatment (%) | Mortality with no endoscopic treatment (%) |
---|---|---|---|---|---|---|
Active bleeding | I | 12–18 | 55–90 | 15–30 | 35 | 11 |
Non-bleeding visible vessel | IIa
Stay updated, free articles. Join our Telegram channelFull access? Get Clinical TreeGet Clinical Tree app for offline access |